

## Tesidolumab

Cat. No.:	HY-P99322
CAS No.:	1531594-08-7
Target:	Complement System
Pathway:	Immunology/Inflammation
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

### BIOLOGICAL ACTIVITY

Description	Tesidolumab (LFG316) is a fully-human IgG1/ $\lambda$ anti-C5 monoclonal antibody of 143 kDa (without glycosylation). Tesidolumab (LFG316) blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex <sup>[1]</sup> .
In Vitro	Tesidolumab (LFG316) possesses a half-life in humans of approximately 9 days. Tesidolumab (LFG316) binds to a distinct epitope to that of eculizumab and ravulizumab, distant to Arg 885 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Jun-Ichi Nishimura, et al. Tesidolumab (LFG316) for treatment of C5-variant patients with paroxysmal nocturnal hemoglobinuria. Haematologica. 2022 Jun 1;107(6):1483-1488.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA